Evaluación de mamíferos medianos y grandes mediante trampas cámara en un bosque montano del norte del Perú

Camera traps are a powerful tool for inventorying elusive and rare species and very useful to obtain ecologi- cal data for plans that involve wildlife conservation. In Peru, several surveys have been carried out in lowland Amazonia especially in the southeastern part of the country, but none in montane cloud forests or Yungas. We present the first camera trap studies produced in Peruvian Yungas at the locality of Querocoto village (Chota, Cajamarca), based on 2002 (dry season) and 1264 (wet season) camera traps-days (CTD). Two localities were surveyed in wet and dry season: The Pagaibamba Protection Forest and the San Lorenzo Forest. The wet season study was carried out in October and November, and the dry season in July to September of 2008. Eight mammalian species were recorded in both seasons. Some 66 (91.7%) independent records were obtained in the dry season, but only six (8.3%) in the wet one, suggesting a seasonality effect. The Mountain Paca Cunicu- lus taczanowskii was the most commonly photographed species, with 17.0 and 1.6 capture frequencies (dry and wet season respectively), whereas the Long-tailed weasel Mustela frenata (0.5 capture frequency in the dry season) was the most rare species. Activity patterns suggest that Mountain Paca C. taczanowskii and the Andean Skunk C. chinga are nocturnal, while Spectacled Bear T. ornatus and Tayra E. barbara are diurnal in the study area. Our records of the Ocelot Leopardus pardalis and the Tayra E. barbara are among the highest altitudinal records known for each species. In addition, the Anta Tapirus pinchaque was also identified by its tracks, representing one of the first record known south of the Huancabamba Depression.Las trampas cámara son una herramienta muy poderosa en el registro de mamíferos raros y elusivos; muy útiles en la obtención de datos ecológicos necesarios para formular planes que involucren la conservación de la fauna. Estos estudios principalmente se han realizado en la Amazonía del Perú especialmente en la parte sur oriental; pero muy pocos en los bosques montanos o yungas. Nosotros presentamos uno de los primeros estudios en las yungas peruanas realizado con trampas cámaras; se llevó a cabo en la localidad de Querocoto (Chota, Cajamarca) con un esfuerzo de muestreo de 2002 (estación seca) y 1264 (estación húmeda) trampas cámara-día (TCD). Dos lugares fueron evaluados en las estaciones húmeda y seca: el bosque de protección de Pagaibamba y el bosque de San Lorenzo. El estudio durante la época húmeda fue llevado a cabo entre octubre y setiembre, mientras la evaluación en época seca fue entre julio y setiembre de 2008. En total se registraron ocho especies de mamíferos. En la época seca se obtuvo 66 (91,7%) de los eventos independientes mientras en la época húmeda solamente seis eventos (8,3%) sugiriendo un efecto por estacionalidad. La Paca de Montaña (Cuniculus taczanowskii) fue el mamífero más fotografiado con frecuencias de captura de 17,0 y 1,6 para época seca y húmeda respectivamente mientras que Mustela frenata con 0,5 fue la especie más rara registrada solo en la época seca. Los patrones de actividad sugieren que la Paca de Montaña, C. taczanowskii y el Zorrillo Andino, Conepatus chinga son nocturnos, mientras que el Oso de Anteojos, Tremarctos ornatus y la Tayra Eira barbara son diurnos en el área de evaluación. Nuestros registros del Ocelote Leopardus pardalis y la Tayra E. barbara están entre los registros altitudinales más altos conocidos para ambas especies. En adición el Anta Tapirus pinchaque fue identificado por medio de sus huellas y representa su primer registro al sur de la depresión de Huancabamba

Gcn4-Mediator Specificity Is Mediated by a Large and Dynamic Fuzzy Protein-Protein Complex.

Transcription activation domains (ADs) are inherently disordered proteins that often target multiple coactivator complexes, but the specificity of these interactions is not understood. Efficient transcription activation by yeast Gcn4 requires its tandem ADs and four activator-binding domains (ABDs) on its target, the Mediator subunit Med15. Multiple ABDs are a common feature of coactivator complexes. We find that the large Gcn4-Med15 complex is heterogeneous and contains nearly all possible AD-ABD interactions. Gcn4-Med15 forms via a dynamic fuzzy protein-protein interface, where ADs bind the ABDs in multiple orientations via hydrophobic regions that gain helicity. This combinatorial mechanism allows individual low-affinity and specificity interactions to generate a biologically functional, specific, and higher affinity complex despite lacking a defined protein-protein interface. This binding strategy is likely representative of many activators that target multiple coactivators, as it allows great flexibility in combinations of activators that can cooperate to regulate genes with variable coactivator requirements

Into the Blue: AO Science with MagAO in the Visible

We review astronomical results in the visible ({\lambda}<1{\mu}m) with adaptive optics. Other than a brief period in the early 1990s, there has been little astronomical science done in the visible with AO until recently. The most productive visible AO system to date is our 6.5m Magellan telescope AO system (MagAO). MagAO is an advanced Adaptive Secondary system at the Magellan 6.5m in Chile. This secondary has 585 actuators with < 1 msec response times (0.7 ms typically). We use a pyramid wavefront sensor. The relatively small actuator pitch (~23 cm/subap) allows moderate Strehls to be obtained in the visible (0.63-1.05 microns). We use a CCD AO science camera called "VisAO". On-sky long exposures (60s) achieve <30mas resolutions, 30% Strehls at 0.62 microns (r') with the VisAO camera in 0.5" seeing with bright R < 8 mag stars. These relatively high visible wavelength Strehls are made possible by our powerful combination of a next generation ASM and a Pyramid WFS with 378 controlled modes and 1000 Hz loop frequency. We'll review the key steps to having good performance in the visible and review the exciting new AO visible science opportunities and refereed publications in both broad-band (r,i,z,Y) and at Halpha for exoplanets, protoplanetary disks, young stars, and emission line jets. These examples highlight the power of visible AO to probe circumstellar regions/spatial resolutions that would otherwise require much larger diameter telescopes with classical infrared AO cameras.Comment: 14 pages, 8 figures, to appear in Proc. SPIE 914

Assessing progress towards meeting major international objectives related to nature and nature's contributions to people

In recognition of the importance of nature, its contributions to people and role in underpinning sustainable development, governments adopted a Strategic Plan on Biodiversity 2011-2020 through the Convention on Biological Diversity (CBD) containing 20 "Aichi Biodiversity Targets" and integrated many of these into the Sustainable Development Goals (SDGs) adopted through the United Nations in 2015. Additional multilateral environmental agreements (MEAs) target particular aspects of nature (e.g., Ramsar Convention on Wetlands; Convention on Migratory Species), drivers of biodiversity loss (e.g., Convention on International Trade in Endangered Species of Wild Fauna and Flora), or responses (e.g., World Heritage Convention). These various MEAs provide complementary fora in which governments strive to coordinate efforts to reduce the loss and degradation of nature, and to promote sustainable development. In this chapter, we assess, through a systematic review process and quantitative analysis of indicators, progress towards the 20 Aichi Targets under the Strategic Plan (and each of the 54 elements or components of these targets), targets under the SDGs that are relevant to nature and nature's contributions to people (NCP), and the goals and targets of six other MEAs. We consider the relationships between the SDGs, nature and the contributions of Indigenous Peoples and Local Communities (IPLCs) to achieving the various targets and goals, the impact of progress or lack of it on IPLCs, the reasons for variation in progress, implications for a new Strategic Plan for Biodiversity beyond 2020, and key knowledge gaps.For the 44 SDG targets assessed, including targets for poverty, hunger, health, water, cities, climate, oceans and land (Goals 1, 2, 3, 6, 11, 13, 14, 15), findings suggest that current negative trends in nature will substantially undermine progress to 22 SDG targets and result in insufficient progress to meet 13 additional targets (i.e. 80 per cent (35 out of 44) of the assessed targets) {3.3.2.1; 3.3.2.2}(established but incomplete). Across terrestrial, aquatic and marine ecosystems, current negative trends in nature and its contributions will hamper SDG progress, with especially poor progress expected towards targets on water security, water quality, ocean pollution and acidification. Trends in nature's contributions relevant to extreme event vulnerability, resource access, small-scale food production, and urban and agricultural sustainability are negative and insufficient for achieving relevant targets under SDGs 1, 2, 3, and 11. This has negative consequences for both the rural and urban poor who are also directly reliant on declining resources for consumption and income generation {3.3.2.2}. For a further 9 targets evaluated in SDGs 1, 3 and 11 a lack of knowledge on how nature contributes to targets (4 targets) or gaps in data with which to assess trends in nature (5 targets) prevented their assessment.Fil: Butchart, Stuart. London Metropolitan University; Reino UnidoFil: Miloslavich, Patricia. University of Western Australia; AustraliaFil: Reyers, Belinda. No especifíca;Fil: Galetto, Leonardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto Multidisciplinario de Biología Vegetal. Universidad Nacional de Córdoba. Facultad de Ciencias Exactas Físicas y Naturales. Instituto Multidisciplinario de Biología Vegetal; ArgentinaFil: Subramanian, Suneetha M.. No especifíca;Fil: Adams, Cristina. No especifíca;Fil: Palomo, Maria Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Museo Argentino de Ciencias Naturales "Bernardino Rivadavia"; ArgentinaFil: McElwee, Pamela. No especifíca;Fil: Meretsky, Vicky J.. No especifíca;Fil: Morsello, Carla. No especifíca;Fil: Nel, Jeanne. No especifíca;Fil: Lynn Newberry, Teresa. No especifíca;Fil: Pacheco, Diego. No especifíca;Fil: Pyhala, Aili. No especifíca;Fil: Rossi Heras, Sergio. No especifíca;Fil: Roy, Joyashree. No especifíca;Fil: Ruiz-Mallén, Isabel. No especifíca;Fil: Salpeteur, Matthieu. No especifíca;Fil: Santos-Martin, Fernando. No especifíca;Fil: Saylor. Kirk. No especifíca;Fil: Schaffartzik, Anke. No especifíca;Fil: Sitas, Nadia. No especifíca;Fil: Speranza, Ifejika. No especifíca;Fil: Suich, Helen. No especifíca;Fil: Tittensor, Derek. No especifíca;Fil: Carignano, Patricia. No especifíca;Fil: Tsioumani, Elsa. No especifíca;Fil: Whitmee, Sarah. No especifíca;Fil: Wilson, Sarah. No especifíca;Fil: Wyndham, Felice. No especifíca;Fil: Zorondo-Rodriguez, Francisco. No especifíca

Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study

Background: In SELECT-PsA 1, a randomised double-blind phase 3 study, upadacitinib 15 mg and 30 mg were superior to placebo and non-inferior to adalimumab in ≥20% improvement in American College of Rheumatology (ACR) criteria at 12 weeks in patients with psoriatic arthritis (PsA). Here, we report 56-week efficacy and safety in patients from SELECT-PsA 1. Methods: Patients received upadacitinib 15 mg or 30 mg once daily, adalimumab 40 mg every other week for 56 weeks or placebo through week 24 switched thereafter to upadacitinib 15 mg or 30 mg until week 56. Efficacy endpoints included the proportion of patients achieving ≥20%/50%/70% improvement in ACR criteria (ACR20/50/70), ≥75%/90%/100% improvement in Psoriasis Area and Severity Index (PASI75/90/100), minimal disease activity (MDA) and change from baseline in modified total Sharp/van der Heijde Score. Treatment-emergent adverse events per 100 patient years (PY) were summarised. Results: Consistent with results through week 24, ACR20/50/70, PASI75/90/100 and MDA responses were maintained with upadacitinib through week 56 and were generally numerically higher than with adalimumab; inhibition of radiographic progression was also maintained. Patients who switched from placebo to upadacitinib exhibited comparable improvements at week 56 as patients originally randomised to upadacitinib. The rates of serious adverse events were 9.1 events/100 PY with upadacitinib 15 mg and 12.3 events/100 PY with upadacitinib 30 mg. Two deaths were reported in each of the upadacitinib groups. Conclusion: Efficacy across various domains of PsA were maintained with upadacitinib 15 mg and 30 mg through week 56 with no new safety signals observed

Implicating genes, pleiotropy, and sexual dimorphism at blood lipid loci through multi-ancestry meta-analysis

Background: Genetic variants within nearly 1000 loci are known to contribute to modulation of blood lipid levels. However, the biological pathways underlying these associations are frequently unknown, limiting understanding of these findings and hindering downstream translational efforts such as drug target discovery. Results: To expand our understanding of the underlying biological pathways and mechanisms controlling blood lipid levels, we leverage a large multi-ancestry meta-analysis (N = 1,654,960) of blood lipids to prioritize putative causal genes for 2286 lipid associations using six gene prediction approaches. Using phenome-wide association (PheWAS) scans, we identify relationships of genetically predicted lipid levels to other diseases and conditions. We confirm known pleiotropic associations with cardiovascular phenotypes and determine novel associations, notably with cholelithiasis risk. We perform sex-stratified GWAS meta-analysis of lipid levels and show that 3-5% of autosomal lipid-associated loci demonstrate sex-biased effects. Finally, we report 21 novel lipid loci identified on the X chromosome. Many of the sex-biased autosomal and X chromosome lipid loci show pleiotropic associations with sex hormones, emphasizing the role of hormone regulation in lipid metabolism. Conclusions: Taken together, our findings provide insights into the biological mechanisms through which associated variants lead to altered lipid levels and potentially cardiovascular disease risk

Implicating genes, pleiotropy, and sexual dimorphism at blood lipid loci through multi-ancestry meta-analysis

Publisher Copyright: © 2022, The Author(s).Background: Genetic variants within nearly 1000 loci are known to contribute to modulation of blood lipid levels. However, the biological pathways underlying these associations are frequently unknown, limiting understanding of these findings and hindering downstream translational efforts such as drug target discovery. Results: To expand our understanding of the underlying biological pathways and mechanisms controlling blood lipid levels, we leverage a large multi-ancestry meta-analysis (N = 1,654,960) of blood lipids to prioritize putative causal genes for 2286 lipid associations using six gene prediction approaches. Using phenome-wide association (PheWAS) scans, we identify relationships of genetically predicted lipid levels to other diseases and conditions. We confirm known pleiotropic associations with cardiovascular phenotypes and determine novel associations, notably with cholelithiasis risk. We perform sex-stratified GWAS meta-analysis of lipid levels and show that 3–5% of autosomal lipid-associated loci demonstrate sex-biased effects. Finally, we report 21 novel lipid loci identified on the X chromosome. Many of the sex-biased autosomal and X chromosome lipid loci show pleiotropic associations with sex hormones, emphasizing the role of hormone regulation in lipid metabolism. Conclusions: Taken together, our findings provide insights into the biological mechanisms through which associated variants lead to altered lipid levels and potentially cardiovascular disease risk.Peer reviewe

Implicating genes, pleiotropy, and sexual dimorphism at blood lipid loci through multi-ancestry meta-analysis

Funding GMP, PN, and CW are supported by NHLBI R01HL127564. GMP and PN are supported by R01HL142711. AG acknowledge support from the Wellcome Trust (201543/B/16/Z), European Union Seventh Framework Programme FP7/2007–2013 under grant agreement no. HEALTH-F2-2013–601456 (CVGenes@Target) & the TriPartite Immunometabolism Consortium [TrIC]-Novo Nordisk Foundation’s Grant number NNF15CC0018486. JMM is supported by American Diabetes Association Innovative and Clinical Translational Award 1–19-ICTS-068. SR was supported by the Academy of Finland Center of Excellence in Complex Disease Genetics (Grant No 312062), the Finnish Foundation for Cardiovascular Research, the Sigrid Juselius Foundation, and University of Helsinki HiLIFE Fellow and Grand Challenge grants. EW was supported by the Finnish innovation fund Sitra (EW) and Finska Läkaresällskapet. CNS was supported by American Heart Association Postdoctoral Fellowships 15POST24470131 and 17POST33650016. Charles N Rotimi is supported by Z01HG200362. Zhe Wang, Michael H Preuss, and Ruth JF Loos are supported by R01HL142302. NJT is a Wellcome Trust Investigator (202802/Z/16/Z), is the PI of the Avon Longitudinal Study of Parents and Children (MRC & WT 217065/Z/19/Z), is supported by the University of Bristol NIHR Biomedical Research Centre (BRC-1215–2001) and the MRC Integrative Epidemiology Unit (MC_UU_00011), and works within the CRUK Integrative Cancer Epidemiology Programme (C18281/A19169). Ruth E Mitchell is a member of the MRC Integrative Epidemiology Unit at the University of Bristol funded by the MRC (MC_UU_00011/1). Simon Haworth is supported by the UK National Institute for Health Research Academic Clinical Fellowship. Paul S. de Vries was supported by American Heart Association grant number 18CDA34110116. Julia Ramierz acknowledges support by the People Programme of the European Union’s Seventh Framework Programme grant n° 608765 and Marie Sklodowska-Curie grant n° 786833. Maria Sabater-Lleal is supported by a Miguel Servet contract from the ISCIII Spanish Health Institute (CP17/00142) and co-financed by the European Social Fund. Jian Yang is funded by the Westlake Education Foundation. Olga Giannakopoulou has received funding from the British Heart Foundation (BHF) (FS/14/66/3129). CHARGE Consortium cohorts were supported by R01HL105756. Study-specific acknowledgements are available in the Additional file 32: Supplementary Note. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services.Peer reviewedPublisher PD

Implicating genes, pleiotropy, and sexual dimorphism at blood lipid loci through multi-ancestry meta-analysis

Abstract Background Genetic variants within nearly 1000 loci are known to contribute to modulation of blood lipid levels. However, the biological pathways underlying these associations are frequently unknown, limiting understanding of these findings and hindering downstream translational efforts such as drug target discovery. Results To expand our understanding of the underlying biological pathways and mechanisms controlling blood lipid levels, we leverage a large multi-ancestry meta-analysis (N = 1,654,960) of blood lipids to prioritize putative causal genes for 2286 lipid associations using six gene prediction approaches. Using phenome-wide association (PheWAS) scans, we identify relationships of genetically predicted lipid levels to other diseases and conditions. We confirm known pleiotropic associations with cardiovascular phenotypes and determine novel associations, notably with cholelithiasis risk. We perform sex-stratified GWAS meta-analysis of lipid levels and show that 3–5% of autosomal lipid-associated loci demonstrate sex-biased effects. Finally, we report 21 novel lipid loci identified on the X chromosome. Many of the sex-biased autosomal and X chromosome lipid loci show pleiotropic associations with sex hormones, emphasizing the role of hormone regulation in lipid metabolism. Conclusions Taken together, our findings provide insights into the biological mechanisms through which associated variants lead to altered lipid levels and potentially cardiovascular disease risk